vidarabine has been researched along with Scleroderma, Systemic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnautovic, I; Burt, RK; Freed, BH; Han, X; Helenowski, IB; Jovanovic, B; Lee, DC; Quigley, K; Shah, SJ | 1 |
1 other study(ies) available for vidarabine and Scleroderma, Systemic
| Article | Year |
|---|---|
Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days.
Topics: Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Scleroderma, Systemic; Transplantation Conditioning; Vidarabine | 2021 |